A novel conjugate of adalimumab and a proprietary glucocorticoid receptor modulator for patients with PMR led to longer time to flare and fewer flares and reduced the glucocorticoid dose needed.
ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with glucocorticoid-dependent polymyalgia rheumatica , with the ability to reduce glucocorticoid dose.
In a phase 2 randomized controlled trial conducted across 70 centers in multiple countries, researchers evaluated the efficacy and safety of a novel antibody-drug conjugate, ABBV-154, in 181 patients with glucocorticoid-dependent PMR who experienced at least two PMR flares while glucocorticoids were being tapered. Patients were randomly assigned to receive either a placebo or ABBV-154 at doses of 40 mg , 150 mg , or 340 mg ; both treatments were administered subcutaneously once every other week alongside a standardized glucocorticoid tapering regimen. The primary endpoint was the time to flare, defined as clinical signs and symptoms of PMR and the need to increase the glucocorticoid dose; the secondary endpoints were achievement of a flare-free state, cumulative glucocorticoid dose, and changes in glucocorticoid dose by week 24. The study was terminated early before the planned primary analysis of data because an interim review indicated that ABBV-154 did not demonstrate a benefit-risk profile sufficiently differentiated from that of existing therapies.Compared with placebo, ABBV-154 extended the time to flare, with a significant reduction in flare risk achieved a flare-free state by week 24 than those on placebo . The same group also demonstrated a greater reduction in pain severity from baseline than the placebo group at week 24 were considered to be possibly related to the ABBV-154 treatment."Given the limited sample size and duration of exposure to study drug, no definite conclusions can be drawn from this study of ABBV-154 in patients with PMR, and caution should be exercised when interpreting the results," the authors wrote."Nevertheless, this study supports that a GRM payload targeted to transmembrane TNF –expressing cells, including activated immune cells, could be beneficial in PMR.”The study was led by Robert F. Spiera, MD, Hospital for Special Surgery, Weill Medical College of Cornell University, New York City. It wasThe early termination of the study limited the sample size and duration of exposure to ABBV-154, affecting the robustness of the findings. The absence of an adalimumab comparator arm limited direct comparisons and the ability to fully assess the contribution of the glucocorticoid receptor modulator payload. Additionally, the PMR activity score was not a primary or secondary endpoint, restricting comparisons with other studies.This study was funded by AbbVie, which participated in the study design, research, data collection, analysis, interpretation of data, reviewing, and approval of this manuscript. Some authors reported having financial relationships with pharmaceutical companies, including AbbVie. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Biologics Glucocorticosteroids Glucocorticoid Therapy Glucocorticoid Hodgkin's Lymphoma Hodgkin Disease Otolaryngology ENT Specialty Head And Neck Surgery ENT Speciality Antibody Drug Conjugates Adcs Receptors Polymyalgia Rheumatica COVID-19 2019 Novel Coronavirus 2019-Ncov Wuhan Coronavirus Human Coronavirus HKU1 Human Coronavirus OC43 Hcov-OC43
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
To Combat Leukemia, Researchers Harness CD37Novel CD37 antibody-drug conjugate shows promise in targeting the Achilles’ heel of acute myeloid leukemia cells.
Read more »
FDA Approves Datopotamab Deruxtecan for HR-Positive, HER2-Negative Metastatic Breast CancerThe US Food and Drug Administration (FDA) has approved datopotamab deruxtecan, a novel antibody drug conjugate, to treat certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This marks the first FDA approval for this type of drug in the US.
Read more »
Myositis Antibody Predictive Value Varies by Antibody Type and IntensityA retrospective study investigated the positive predictive value (PPV) of 17 myositis antibodies for diagnosing myositis and related conditions. The study found that greater diagnostic accuracy is associated with stronger antibody band intensities and the simultaneous presence of two or more myositis antibodies. Anti-HMGCR antibodies demonstrated the highest PPV for myositis diagnosis at 94%.
Read more »
New Drug Regimens Offer Hope in Fight Against Drug-Resistant TBInternational clinical trial identifies three new regimens for rifampin-resistant TB, using recently discovered drugs to provide shorter, personalized treatment with fewer side effects. WHO recommends these regimens, boosting access to life-saving care for vulnerable populations.
Read more »
Trump Reverses Biden Prescription Drug Order, Raising Concerns About Drug PricesPresident Donald Trump's early executive order rescinding a Biden-era prescription drug policy has sparked worries about escalating drug costs for millions of Medicare and Medicaid recipients. The move, characterized by the Trump administration as targeting 'deeply unpopular' and 'radical' Biden policies, overturns efforts to negotiate lower drug prices and expand access to affordable medications.
Read more »
New Drug Regimens Offer Hope in Fight Against Drug-Resistant TuberculosisAn international clinical trial has discovered three highly effective drug regimens for treating tuberculosis resistant to rifampin, a key antibiotic used in TB treatment. These findings, published in the New England Journal of Medicine, could significantly improve patient outcomes and transform the fight against this global health crisis.
Read more »